富含亮氨酸的α-2 糖蛋白是评估炎症性肠病临床和内镜疾病活动的可靠血清生物标志物。
Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
机构信息
Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
出版信息
Inflamm Bowel Dis. 2023 Sep 1;29(9):1399-1408. doi: 10.1093/ibd/izac230.
BACKGROUND
Leucine-rich alpha-2 glycoprotein (LRG) is a novel serum biomarker for inflammation in inflammatory bowel disease (IBD). This prospective study aimed to compare the value of LRG with C-reactive protein (CRP) and fecal calprotectin for evaluating clinical and endoscopic disease activity in patients with IBD.
METHODS
At entry, clinical and endoscopic disease activity was assessed in 267 patients with IBD (ulcerative colitis [UC] 203; Crohn's disease [CD] 64), and the levels of LRG, CRP and fecal calprotectin were measured. The accuracy of the biomarkers for the detection of clinical and endoscopic disease activity was determined by the area under the receiver operating characteristic curve.
RESULTS
Leucine-rich alpha-2 glycoprotein showed a significant relationship with the clinical and endoscopic severity in both UC and CD (both diseases, P < .0001). In the clinical assessment of UC, the accuracy of LRG was significantly higher than that of CRP (0.73 vs 0.63; P < .001). In the endoscopic assessment of UC, the accuracy of LRG was significantly higher than that of CRP (P = .01), but it was significantly lower than that of fecal calprotectin (P = .009; LRG, 0.80; CRP, 0.72; fecal calprotectin, 0.91). In the clinical and endoscopic assessment of CD, the accuracy was not significantly different between the biomarkers (clinical activity: LRG, 0.71; CRP, 0.64; fecal calprotectin, 0.66; in endoscopic activity: LRG, 0.79; CRP, 0.78; fecal calprotectin, 0.81).
CONCLUSIONS
Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for the assessment of clinical and endoscopic disease activity in patients with IBD. It can be an alternative to CRP for the assessment of UC.
背景
富含亮氨酸的α-2 糖蛋白（LRG）是炎症性肠病（IBD）炎症的新型血清生物标志物。本前瞻性研究旨在比较 LRG 与 C 反应蛋白（CRP）和粪便钙卫蛋白在评估 IBD 患者的临床和内镜疾病活动中的价值。
方法
在 267 例 IBD 患者（溃疡性结肠炎[UC]203 例；克罗恩病[CD]64 例）入组时，评估其临床和内镜疾病活动，并测量 LRG、CRP 和粪便钙卫蛋白水平。通过接受者操作特征曲线下的面积来确定生物标志物检测临床和内镜疾病活动的准确性。
结果
LRG 与 UC 和 CD 的临床和内镜严重程度均呈显著相关（两种疾病，P<0.0001）。在 UC 的临床评估中，LRG 的准确性明显高于 CRP（0.73 对 0.63；P<0.001）。在 UC 的内镜评估中，LRG 的准确性明显高于 CRP（P=0.01），但明显低于粪便钙卫蛋白（P=0.009；LRG，0.80；CRP，0.72；粪便钙卫蛋白，0.91）。在 CD 的临床和内镜评估中，生物标志物的准确性无显著差异（临床活动：LRG，0.71；CRP，0.64；粪便钙卫蛋白，0.66；内镜活动：LRG，0.79；CRP，0.78；粪便钙卫蛋白，0.81）。
结论
LRG 是评估 IBD 患者临床和内镜疾病活动的可靠血清生物标志物。它可以替代 CRP 用于 UC 的评估。
Zotero 插件